Daiichi and Zymeworks end antibody pact after seven years
Zymeworks and Daiichi Sankyo ended a seven-year collaboration on bispecific antibodies last week.
Under the 2016 agreement, Zymeworks licensed its Azymetric and Efect platforms to Daiichi Sankyo to develop one bispecific antibody therapy in exchange for technology access fees and milestone payments and royalties, according to SEC filings. But Zymeworks also got something else in return, in the form of licenses to certain immuno-oncology antibodies from Daiichi.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.